CXCL13 shapes immunoactive tumor microenvironment and enhances the efficacy of PD-1 checkpoint blockade in high-grade serous ovarian cancer

CXCL13型 CXCR5型 癌症研究 细胞毒性T细胞 肿瘤微环境 离体 免疫检查点 CD8型 卵巢癌 医学 趋化因子 免疫疗法 CD20 免疫学 癌症 免疫系统 内科学 生物 趋化因子受体 免疫组织化学 体内 体外 生物化学 生物技术
作者
Moran Yang,Jiaqi Lü,Guodong Zhang,Yiying Wang,Mengdi He,Qing Xu,Congjian Xu,Haiou Liu
出处
期刊:Journal for ImmunoTherapy of Cancer [BMJ]
卷期号:9 (1): e001136-e001136 被引量:67
标识
DOI:10.1136/jitc-2020-001136
摘要

Most patients with high-grade serous ovarian cancer (HGSC) lack an effective response to immune checkpoint blockade, highlighting the need for more knowledge about what is required for successful treatment. As follicular cytotoxic CXCR5+CD8+ T cells are maintained by reinvigoration by immune checkpoint blockade in tumors, we attempted to reveal the relationship between CXCR5+CD8+ T cells and the tumor microenvironment to predict immunotherapy responses in HGSC.264 patients with HGSC from two cohorts and 340 HGSC cases from The Cancer Genome Atlas cohort were enrolled. Ex vivo and in vivo studies were conducted with human HGSC tumors and murine tumor models. The spatial correlation between CXC-chemokine ligand 13 (CXCL13), CXCR5, CD8, and CD20 was evaluated by immunohistochemistry and immunofluorescence. Survival was compared between different subsets of patients using Kaplan-Meier analysis. The therapeutic effect of CXCL13 and programmed cell death-1 (PD-1) blockade was validated using human HGSC tumors and murine models.High CXCL13 expression was associated with prolonged survival. Tumors with high CXCL13 expression exhibited increased infiltration of activated and CXCR5-expressing CD8+ T cells. Incubation with CXCL13 facilitated expansion and activation of CXCR5+CD8+ T cells ex vivo. CXCR5+CD8+ T cells appeared in closer proximity to CXCL13 in tumors and chemotaxis towards CXCL13 in vitro. The combination of CXCL13, CXCR5, and CD8+ T cells was an independent predictor for survival. In addition, CXCL13 was associated with clusters of CD20+ B cells. CD20+ B cells predicted better patient survival in the presence of CXCL13. Histological evaluation highlighted colocalization of CXCL13 with tertiary lymphoid structures (TLSs). TLSs carried prognostic benefit only in the presence of CXCL13. CXCL13 in combination with anti-PD-1 therapy retarded tumor growth in a CD8+ T-cell-dependent manner, resulting in increased infiltration of cytotoxic CD8+ T cells and CXCR5+CD8+ T cells.These data define a critical role of CXCL13 in shaping antitumor microenvironment by facilitating the maintenance of CXCR5+CD8+ T cells in TLSs and support a clinical investigation for a combination of CXCL13 and PD-1 blockade therapy in HGSC.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
大幅提高文件上传限制,最高150M (2024-4-1)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
1秒前
充电宝应助Monica采纳,获得10
1秒前
苗槐完成签到,获得积分10
2秒前
无花果应助xiao采纳,获得10
2秒前
conanyangqun完成签到,获得积分10
2秒前
bamiaojinyu完成签到 ,获得积分10
3秒前
3秒前
黄威完成签到,获得积分10
3秒前
5秒前
小陈发布了新的文献求助10
5秒前
jiu完成签到,获得积分10
6秒前
7秒前
现代发带完成签到,获得积分10
8秒前
Anthocyanidin发布了新的文献求助10
8秒前
9秒前
魏志浩发布了新的文献求助10
9秒前
9秒前
采鹿鸣完成签到,获得积分10
10秒前
123完成签到,获得积分10
11秒前
安诺完成签到,获得积分10
11秒前
zhaoxiaonuan发布了新的文献求助10
13秒前
qianshu完成签到,获得积分0
13秒前
小吉麻麻完成签到,获得积分10
13秒前
14秒前
叶箴完成签到,获得积分10
14秒前
Dailei完成签到,获得积分10
14秒前
小岳同学完成签到,获得积分10
14秒前
小鹿斑比完成签到 ,获得积分10
14秒前
meimei完成签到 ,获得积分10
15秒前
拼搏马里奥完成签到,获得积分10
17秒前
kellyzzm完成签到,获得积分10
17秒前
躺平的搬砖人完成签到,获得积分10
17秒前
叶箴发布了新的文献求助10
18秒前
星辰大海应助泥肿大采纳,获得10
18秒前
奋斗醉冬完成签到,获得积分10
18秒前
19秒前
嘉然的狗完成签到,获得积分20
21秒前
guanzhuang完成签到,获得积分10
21秒前
CFT完成签到,获得积分10
22秒前
狼主完成签到 ,获得积分10
23秒前
高分求助中
The three stars each : the Astrolabes and related texts 1070
Manual of Clinical Microbiology, 4 Volume Set (ASM Books) 13th Edition 1000
Sport in der Antike 800
De arte gymnastica. The art of gymnastics 600
少脉山油柑叶的化学成分研究 530
Sport in der Antike Hardcover – March 1, 2015 500
Boris Pesce - Gli impiegati della Fiat dal 1955 al 1999 un percorso nella memoria 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 有机化学 工程类 生物化学 纳米技术 物理 内科学 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 电极 光电子学 量子力学
热门帖子
关注 科研通微信公众号,转发送积分 2407540
求助须知:如何正确求助?哪些是违规求助? 2104269
关于积分的说明 5311273
捐赠科研通 1831840
什么是DOI,文献DOI怎么找? 912764
版权声明 560691
科研通“疑难数据库(出版商)”最低求助积分说明 488042